Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)

• Status: Recruiting
• Trial end date: 2023-09-20
• Target enrollment: 0
• Participant gender: All

Summary

Obecholic acid is a modified bile acid and Farnesoid X receptor (FXR) agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion. Conventional therapy with obecholic acid will improve liver function of patients with PBC.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Criteria

Inclusion Criteria:

1. Male or female aged 18 to 75 years.

2. Meet at least 2 of the following 3 PBC diagnoses:

1. Patients had elevated alkaline phosphatase for at least 3 months before enrolment.

2. AMA positive (titer ≥1:40), or if AMA negative, PBC specific antibodies (anti- GP210 and/or anti-SP100 and/or AMA-M2) are required.

3. Liver biopsy suggested PBC 48 weeks before enrollment.

3. ALP > 1.67× ULN before enrollment.

4. Taking UDCA with stable dose for at least 3 months before enrollment.

Exclusion Criteria:

1. Merging with other virus infected.

2. With other existing liver disease or a history of liver disease.

3. With clinical complications of PBC or clinically significant hepatic decompensation.

4. Child-pugh grade B or C.

5. Creatinine (Cr) ≥ 1.5×ULN and serum creatinine clearance rate < 60mL/min; [Calculation formula: Cr:(140-age)×weight(kg) /0.818 × Scr (μmol/L)，female Cr=Cr × 0.85].

6. ALT or AST>5×ULN;Tbil > 2×ULN.

7. Patients with a history of severe pruritus 2 months before enrollment.

8. The presence of clinically relevant arrhythmias or associated history that may affect survival during the study period.

9. With diseases that may cause nonhepatic ALP increases (e.g., Paget's disease) or which may diminish life expectancy to < 2 years.